Calyxt Inc (CLXT) Sets New 1-Year High at $29.65

Calyxt Inc (NASDAQ:CLXT)’s share price reached a new 52-week high during trading on Wednesday . The company traded as high as $29.65 and last traded at $30.05, with a volume of 41,641 shares traded. The stock had previously closed at $29.09.

A number of equities analysts have recently commented on the stock. Wells Fargo & Company raised their price objective on shares of Calyxt from $17.00 to $30.00 and gave the stock an “outperform” rating in a report on Friday, September 29th. Citigroup Inc. downgraded shares of Calyxt from a “buy” rating to a “neutral” rating in a report on Wednesday, September 27th. Finally, Jefferies Group LLC assumed coverage on shares of Calyxt in a report on Monday, August 14th. They set a “buy” rating and a $16.00 price objective for the company.

The stock’s market capitalization is $569.97 million. The stock has a 50 day moving average price of $23.47 and a 200 day moving average price of $19.15.

TRADEMARK VIOLATION NOTICE: “Calyxt Inc (CLXT) Sets New 1-Year High at $29.65” was first posted by Stock Observer and is owned by of Stock Observer. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.thestockobserver.com/2017/10/13/calyxt-inc-clxt-sets-new-1-year-high-at-29-65.html.

Calyxt Company Profile

Calyxt, Inc is a food and agriculture company. The Company is focused on delivering healthier specialty food ingredients, such as healthier oils and high fiber wheat, for consumers and agriculturally advantageous crop traits, such as herbicide tolerance to farmers. The Company also combines gene-editing technology and technical that enables to edit a plant genome to elicit the desired traits and characteristics.

Receive News & Ratings for Calyxt Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply